Tuesday, November 11, 2025 10:45:50 AM
Total dilution in Nov-2025 so far:
0 + 4,534,048 + 1500000 + 2,372,961 = 8,407,009
Total dilution in October-2025 :
963,856 + 1,591,703 + 2,612,594 + 4,887,246 + 567,601 + 1,264,542 + 2,088,184 = 13,975,726
Total dilution in September-2025:
4,810,468 + 2,421,740 + 2,972,626 + 1,743,082 + 1,256,729 + 3,561,564 = 16,766,209
Dilution: Mon 11/10
1,540,682,082 - 1,538,309,121 = 2,372,961
Dilution: Fri 11/07
1,538,309,121 - 1,538,309,121 = 0
Dilution: Thur 11/06
1,538,309,121 - 1,538,309,121 = 0
Dilution: Wed 11/05
1,538,309,121 - 1,536,809,121 = 1,500,000
Dilution: Tue 11/04
1,536,809,121 - 1,532,275,073= 4,534,048
Dilution: Mon 11/03
1,532,275,073 - 1,532,275,073= 0
0 + 4,534,048 + 1500000 + 2,372,961 = 8,407,009
Total dilution in October-2025 :
963,856 + 1,591,703 + 2,612,594 + 4,887,246 + 567,601 + 1,264,542 + 2,088,184 = 13,975,726
Total dilution in September-2025:
4,810,468 + 2,421,740 + 2,972,626 + 1,743,082 + 1,256,729 + 3,561,564 = 16,766,209
Dilution: Mon 11/10
1,540,682,082 - 1,538,309,121 = 2,372,961
Dilution: Fri 11/07
1,538,309,121 - 1,538,309,121 = 0
Dilution: Thur 11/06
1,538,309,121 - 1,538,309,121 = 0
Dilution: Wed 11/05
1,538,309,121 - 1,536,809,121 = 1,500,000
Dilution: Tue 11/04
1,536,809,121 - 1,532,275,073= 4,534,048
Dilution: Mon 11/03
1,532,275,073 - 1,532,275,073= 0
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
